SG10201605572TA - Antibody variants and uses thereof - Google Patents
Antibody variants and uses thereofInfo
- Publication number
- SG10201605572TA SG10201605572TA SG10201605572TA SG10201605572TA SG10201605572TA SG 10201605572T A SG10201605572T A SG 10201605572TA SG 10201605572T A SG10201605572T A SG 10201605572TA SG 10201605572T A SG10201605572T A SG 10201605572TA SG 10201605572T A SG10201605572T A SG 10201605572TA
- Authority
- SG
- Singapore
- Prior art keywords
- antibody variants
- variants
- antibody
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2887—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD20
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/36—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against blood coagulation factors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
- C07K2317/524—CH2 domain
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
- C07K2317/526—CH3 domain
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/71—Decreased effector function due to an Fc-modification
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K2317/734—Complement-dependent cytotoxicity [CDC]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/77—Internalization into the cell
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Hematology (AREA)
- Veterinary Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Animal Behavior & Ethology (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201161504994P | 2011-07-06 | 2011-07-06 | |
DKPA201100519 | 2011-07-06 | ||
DKPA201200371 | 2012-05-30 |
Publications (1)
Publication Number | Publication Date |
---|---|
SG10201605572TA true SG10201605572TA (en) | 2016-09-29 |
Family
ID=47437504
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG10201605572TA SG10201605572TA (en) | 2011-07-06 | 2012-07-06 | Antibody variants and uses thereof |
Country Status (21)
Country | Link |
---|---|
US (2) | US10759867B2 (es) |
EP (2) | EP3970746A3 (es) |
JP (2) | JP6243330B2 (es) |
KR (2) | KR102163669B1 (es) |
CN (3) | CN112239496A (es) |
AU (4) | AU2012280222B8 (es) |
BR (1) | BR112014000264A2 (es) |
CA (1) | CA2840147A1 (es) |
DK (1) | DK2729170T3 (es) |
EA (1) | EA201400108A1 (es) |
ES (1) | ES2908876T3 (es) |
IN (1) | IN2014CN00807A (es) |
MX (1) | MX357944B (es) |
PL (1) | PL2729170T3 (es) |
PT (1) | PT2729170T (es) |
RS (1) | RS63044B1 (es) |
SG (1) | SG10201605572TA (es) |
SI (1) | SI2729170T1 (es) |
UA (1) | UA117901C2 (es) |
WO (1) | WO2013004842A2 (es) |
ZA (1) | ZA201309499B (es) |
Families Citing this family (114)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP5624276B2 (ja) | 2006-03-31 | 2014-11-12 | 中外製薬株式会社 | 抗体の血中動態を制御する方法 |
JP5334319B2 (ja) | 2007-09-26 | 2013-11-06 | 中外製薬株式会社 | Cdrのアミノ酸置換により抗体の等電点を改変する方法 |
KR20220162801A (ko) | 2008-04-11 | 2022-12-08 | 추가이 세이야쿠 가부시키가이샤 | 복수 분자의 항원에 반복 결합하는 항원 결합 분자 |
AU2011268110B2 (en) | 2010-06-19 | 2016-05-19 | Memorial Sloan-Kettering Cancer Center | Anti-GD2 antibodies |
EP2647706B1 (en) | 2010-11-30 | 2023-05-17 | Chugai Seiyaku Kabushiki Kaisha | Antigen-binding molecule capable of binding to plurality of antigen molecules repeatedly |
EP2679681B2 (en) | 2011-02-25 | 2023-11-15 | Chugai Seiyaku Kabushiki Kaisha | FcgammaRIIB-specific FC antibody |
EP2729496B8 (en) * | 2011-07-06 | 2017-10-18 | Genmab A/S | Modulation of complement-dependent cytotoxicity through modifications of the c-terminus of antibody heavy chains |
KR20200120743A (ko) * | 2011-07-06 | 2020-10-21 | 젠맵 비. 브이 | 항체 변이체 및 그의 용도 |
UA117901C2 (uk) * | 2011-07-06 | 2018-10-25 | Ґенмаб Б.В. | Спосіб посилення ефекторної функції вихідного поліпептиду, його варіанти та їх застосування |
WO2013047748A1 (ja) | 2011-09-30 | 2013-04-04 | 中外製薬株式会社 | 複数の生理活性を有する抗原の消失を促進する抗原結合分子 |
TW201817744A (zh) * | 2011-09-30 | 2018-05-16 | 日商中外製藥股份有限公司 | 具有促進抗原清除之FcRn結合域的治療性抗原結合分子 |
WO2013081143A1 (ja) | 2011-11-30 | 2013-06-06 | 中外製薬株式会社 | 免疫複合体を形成する細胞内への運搬体(キャリア)を含む医薬 |
KR102041412B1 (ko) * | 2011-12-30 | 2019-11-11 | 한미사이언스 주식회사 | 면역글로불린 Fc 단편 유도체 |
US20130236890A1 (en) * | 2012-03-08 | 2013-09-12 | HI-STEM Heidelberg Institute for Stem Cell Technology and Experimental Medicine gGmbH | Novel method for analyzing circulating tumor cells of a patient for the presence of metastasis-initiating cells |
IN2014DN09417A (es) | 2012-05-10 | 2015-07-17 | Bioatla Llc | |
DK2869845T3 (da) * | 2012-07-06 | 2019-12-09 | Genmab Bv | Dimert protein med tredobbelte mutationer |
EP3632462A1 (en) * | 2012-07-06 | 2020-04-08 | Genmab B.V. | Dimeric protein with triple mutations |
EP2869845B1 (en) | 2012-07-06 | 2019-08-28 | Genmab B.V. | Dimeric protein with triple mutations |
BR112015001955A2 (pt) | 2012-08-24 | 2017-11-07 | Chugai Pharmaceutical Co Ltd | variante de região fc específica de fcgamariib |
AU2013372331A1 (en) * | 2013-01-10 | 2015-07-23 | Genmab B.V. | Human IgG1 Fc region variants and uses thereof |
CN105705165B (zh) * | 2013-03-15 | 2020-04-24 | 纪念斯隆-凯特琳癌症中心 | 高亲和力抗gd2抗体 |
MX368258B (es) | 2013-03-15 | 2019-09-25 | Zymeworks Inc | Compuestos citotoxicos y antimitoticos y metodos de uso de los mismos. |
WO2014145159A2 (en) * | 2013-03-15 | 2014-09-18 | Permeon Biologics, Inc. | Charge-engineered antibodies or compositions of penetration-enhanced targeting proteins and methods of use |
WO2014163101A1 (ja) | 2013-04-02 | 2014-10-09 | 中外製薬株式会社 | Fc領域改変体 |
JP2016528167A (ja) | 2013-04-29 | 2016-09-15 | エフ.ホフマン−ラ ロシュ アーゲーF. Hoffmann−La Roche Aktiengesellschaft | ヒトFcRn結合改変抗体及び使用方法 |
KR102384740B1 (ko) | 2013-12-27 | 2022-04-07 | 자임워크스 인코포레이티드 | 약물 접합체를 위한 설폰아마이드-함유 연결 시스템 |
EP3092252B1 (en) | 2014-01-08 | 2019-09-18 | The U.S.A. as represented by the Secretary, Department of Health and Human Services | Antibody targeting cell surface deposited complement protein c3d and use thereof |
BR112016014969A2 (pt) * | 2014-01-15 | 2018-01-23 | Hoffmann La Roche | polipeptídeo, formulação farmacêutica e uso de um polipeptídeo |
BR112016016416A2 (pt) | 2014-01-15 | 2017-10-03 | Hoffmann La Roche | VARIANTES DE REGIÕES-"Fc" COM 'FcRn' MODIFICADAS E PROPRIEDADES DE LIGAÇÃO DE PROTEÍNA "A" MANTIDAS |
CA2931979A1 (en) * | 2014-01-15 | 2015-07-23 | F. Hoffmann-La Roche Ag | Fc-region variants with modified fcrn-binding properties |
CA2939198A1 (en) | 2014-03-05 | 2015-09-11 | Ucb Biopharma Sprl | Multimeric fc proteins |
BR112016027912A2 (pt) * | 2014-05-29 | 2018-02-20 | Macrogenics, Inc. | molécula de ligação triespecífica capaz de se ligar de maneira imunoespecífica a três epítopos diferentes, composição farmacêutica, método de tratamento de câncer, método de tratamento de uma doença associada à presença de um patógeno, anticorpo anti-ror1, ou fragmento de ligação a ror1, fragmento de anticorpo biespecífico, bite ou anticorpo de cadeia simples, e método de tratamento de câncer |
HUE057768T2 (hu) | 2014-09-17 | 2022-06-28 | Zymeworks Inc | Citotoxikus és antimitotikus vegyületek és azok alkalmazásának módszerei |
WO2016097300A1 (en) * | 2014-12-19 | 2016-06-23 | Genmab A/S | Rodent bispecific heterodimeric proteins |
MX2017012805A (es) | 2015-04-07 | 2018-04-11 | Genentech Inc | Complejo de unión a antígenos con actividad agonista y métodos de uso. |
MX2017014908A (es) | 2015-05-21 | 2018-08-15 | Harpoon Therapeutics Inc | Proteinas de union triespecificas y metodos de uso. |
JP6983075B2 (ja) | 2015-06-02 | 2021-12-17 | ノヴォ ノルディスク アー/エス | 極性の組換え延長部を有するインスリン |
MA43348A (fr) | 2015-10-01 | 2018-08-08 | Novo Nordisk As | Conjugués de protéines |
CA3007033A1 (en) * | 2015-12-01 | 2017-06-08 | Genmab B.V. | Anti-dr5 antibodies and methods of use thereof |
WO2017132457A1 (en) * | 2016-01-28 | 2017-08-03 | Janssen Biotech, Inc. | BISPECIFIC ANTI-TNF-α/IL-17A ANTIBODIES AND ANTI-TNF-α ANTIBODIES AND METHODS OF THEIR USE |
CA3016563A1 (en) | 2016-03-21 | 2017-09-28 | Elstar Therapeutics, Inc. | Multispecific and multifunctional molecules and uses thereof |
WO2017177175A1 (en) * | 2016-04-07 | 2017-10-12 | The George Washington University | Methods and compositions targeting retroviral latency |
AU2017266288A1 (en) * | 2016-05-18 | 2019-01-03 | Genmab B.V. | Antibodies and methods of use thereof in treatment of infectious disease |
US11623958B2 (en) | 2016-05-20 | 2023-04-11 | Harpoon Therapeutics, Inc. | Single chain variable fragment CD3 binding proteins |
KR102530742B1 (ko) | 2016-05-20 | 2023-05-09 | 하푼 테라퓨틱스, 인크. | 단일 도메인 혈청 알부민 결합 단백질 |
CA3033665A1 (en) * | 2016-08-12 | 2018-02-15 | Janssen Biotech, Inc. | Fc engineered anti-tnfr superfamily member antibodies having enhanced agonistic activity and methods of using them |
PT3445787T (pt) | 2016-10-07 | 2021-03-15 | Tcr2 Therapeutics Inc | Composições e métodos para reprogramação de recetores de célula t com o uso de proteínas de fusão |
CN110461868A (zh) * | 2016-11-01 | 2019-11-15 | 根马布私人有限公司 | 多肽变体及其用途 |
EP3544629A4 (en) | 2016-11-23 | 2020-06-17 | Harpoon Therapeutics, Inc. | TRISPECIFIC PROTEINS CIBLANG PSMA AND METHODS OF USE |
KR102275008B1 (ko) | 2016-11-23 | 2021-07-13 | 하푼 테라퓨틱스, 인크. | 전립선 특이 막 항원 결합 단백질 |
US10440535B2 (en) | 2017-01-25 | 2019-10-08 | The George Washington University | System and method for asset-agnostic wireless monitoring and predictive maintenance of deployed assets |
CN110945021A (zh) * | 2017-02-10 | 2020-03-31 | 根马布私人有限公司 | 多肽变体及其用途 |
US20200291089A1 (en) | 2017-02-16 | 2020-09-17 | Elstar Therapeutics, Inc. | Multifunctional molecules comprising a trimeric ligand and uses thereof |
US11535668B2 (en) | 2017-02-28 | 2022-12-27 | Harpoon Therapeutics, Inc. | Inducible monovalent antigen binding protein |
AU2018244574A1 (en) * | 2017-03-28 | 2019-10-31 | Lyvgen Biopharma Holdings Limited | Therapeutic agents and methods for enhancing immune responses in tumor microenvironment |
BR112019020219A2 (pt) | 2017-03-31 | 2020-11-24 | Genmab Holding B.V. | anticorpo biespecífico, anticorpo anti-cd37, composição farmacêutica, uso do anticorpo biespecífico, do anticorpo anti-cd37 ou da composição farmacêutica, método para induzir a morte celular, ou inibir o crescimento e/ou a proliferação de uma célula tumoral que expressa cd37, método de tratamento, construto de ácido nucleico, vetor de expressão, célula hospedeira, anticorpo anti-idiotípico, e, método in vitro para detectar a presença de um antígeno cd37 humano ou uma célula que expressa cd37 humano. |
EP3606560A2 (en) | 2017-04-05 | 2020-02-12 | Novo Nordisk A/S | Oligomer extended insulin-fc conjugates |
AU2018265856B2 (en) | 2017-05-12 | 2023-04-27 | Harpoon Therapeutics, Inc. | Mesothelin binding proteins |
WO2018222901A1 (en) | 2017-05-31 | 2018-12-06 | Elstar Therapeutics, Inc. | Multispecific molecules that bind to myeloproliferative leukemia (mpl) protein and uses thereof |
BR112019025328A2 (pt) | 2017-06-07 | 2020-06-23 | Genmab B.V. | Composição farmacêutica, uso da composição farmacêutica, métodos para tratar um indivíduo tendo um câncer e para preparar uma composição farmacêutica, e, kit de partes. |
WO2019035938A1 (en) | 2017-08-16 | 2019-02-21 | Elstar Therapeutics, Inc. | MULTISPECIFIC MOLECULES BINDING TO BCMA AND USES THEREOF |
CN111132998B (zh) * | 2017-09-25 | 2024-01-30 | 苏州丁孚靶点生物技术有限公司 | 用于癌症治疗的方法和组合物 |
CN111630070A (zh) | 2017-10-13 | 2020-09-04 | 哈普恩治疗公司 | 三特异性蛋白质及使用方法 |
BR112020007249B1 (pt) | 2017-10-13 | 2022-11-22 | Harpoon Therapeutics, Inc | Roteína de ligação a antígeno de maturação de célula b, proteína de ligação multiespecífica e uso das referidas proteínas |
MA51666A (fr) | 2018-01-24 | 2020-12-02 | Genmab Bv | Variants polypeptidiques et leurs utilisations |
JP2018138022A (ja) * | 2018-02-23 | 2018-09-06 | ゲンマブ ビー.ブイ. | ヒトIgG1 Fc領域変異体およびその使用 |
EP3765517A1 (en) | 2018-03-14 | 2021-01-20 | Elstar Therapeutics, Inc. | Multifunctional molecules that bind to calreticulin and uses thereof |
WO2019178364A2 (en) | 2018-03-14 | 2019-09-19 | Elstar Therapeutics, Inc. | Multifunctional molecules and uses thereof |
WO2019211472A1 (en) | 2018-05-03 | 2019-11-07 | Genmab B.V. | Antibody variant combinations and uses thereof |
JP2021528439A (ja) * | 2018-06-22 | 2021-10-21 | ゲンマブ ホールディング ビー.ブイ. | 抗cd37抗体および抗cd20抗体、組成物、ならびにそれらの使用方法 |
WO2019243626A1 (en) | 2018-06-22 | 2019-12-26 | Genmab A/S | Method for producing a controlled mixture of two or more different antibodies |
EP3814369A1 (en) | 2018-06-29 | 2021-05-05 | Stichting Het Nederlands Kanker Instituut- Antoni van Leeuwenhoek Ziekenhuis | Tweak-receptor agonists for use in combination with immunotherapy of a cancer |
US11845797B2 (en) | 2018-07-03 | 2023-12-19 | Marengo Therapeutics, Inc. | Anti-TCR antibody molecules and uses thereof |
MA53122A (fr) * | 2018-07-13 | 2021-05-19 | Genmab As | Variants d'anticorps cd38 et leurs utilisations |
MA53123A (fr) | 2018-07-13 | 2021-05-19 | Genmab As | Thérapie à médiation par trogocytose utilisant des anticorps cd38 |
US20210355219A1 (en) * | 2018-09-21 | 2021-11-18 | Harpoon Therapeutics, Inc. | Conditionally activated target-binding molecules |
CA3114038A1 (en) | 2018-09-25 | 2020-04-02 | Harpoon Therapeutics, Inc. | Dll3 binding proteins and methods of use |
WO2020067541A1 (ja) * | 2018-09-28 | 2020-04-02 | 協和キリン株式会社 | 抗体組成物 |
US20220002432A1 (en) * | 2018-11-16 | 2022-01-06 | Virtuoso Binco, Inc. | Cd38 and icam1 antibodies and uses thereof |
JP2022521937A (ja) | 2019-02-21 | 2022-04-13 | マレンゴ・セラピューティクス,インコーポレーテッド | NKp30に結合する抗体分子およびその使用 |
CN114126714A (zh) | 2019-02-21 | 2022-03-01 | 马伦戈治疗公司 | 抗tcr抗体分子及其用途 |
CN114127112A (zh) | 2019-02-21 | 2022-03-01 | 马伦戈治疗公司 | 与t细胞结合的多功能分子及其治疗自身免疫性病症的用途 |
CA3131016A1 (en) | 2019-02-21 | 2020-08-27 | Andreas Loew | Multifunctional molecules that bind to calreticulin and uses thereof |
SG11202109061YA (en) | 2019-02-21 | 2021-09-29 | Marengo Therapeutics Inc | Multifunctional molecules that bind to t cell related cancer cells and uses thereof |
JP2022531894A (ja) | 2019-05-09 | 2022-07-12 | ゲンマブ ビー.ブイ. | がんの処置において使用するための抗dr5抗体の組み合わせの投与レジメン |
GB201910900D0 (en) | 2019-07-31 | 2019-09-11 | Scancell Ltd | Modified fc-regions to enhance functional affinity of antibodies and antigen binding fragments thereof |
EP4055046A1 (en) | 2019-11-06 | 2022-09-14 | Genmab B.V. | Antibody variant combinations and uses thereof |
CA3160855A1 (en) | 2019-12-09 | 2021-06-17 | Adrian Wiestner | Antibodies targeting cell surface deposited complement protein c3d and use thereof |
CN113121677B (zh) * | 2019-12-31 | 2023-06-27 | 周易 | 一种得到高纯度异源抗体的方法 |
EP4084821A4 (en) | 2020-01-03 | 2024-04-24 | Marengo Therapeutics Inc | CD33-BINDING MULTIFUNCTIONAL MOLECULES AND THEIR USES |
MX2022008050A (es) | 2020-01-16 | 2022-07-27 | Genmab As | Formulaciones de anticuerpos anti cumulo de diferenciacion 38 (cd38) y usos de las mismas. |
CN114945597A (zh) * | 2020-01-17 | 2022-08-26 | 艾提欧生物疗法有限公司 | 降低脱靶毒性的前抗体 |
CA3170833A1 (en) | 2020-02-21 | 2021-08-26 | Harpoon Therapeutics, Inc. | Flt3 binding proteins and methods of use |
KR20230028242A (ko) | 2020-04-24 | 2023-02-28 | 마렝고 테라퓨틱스, 인크. | T 세포 관련 암 세포에 결합하는 다중기능성 분자 및 그것의 용도 |
CN115461078A (zh) * | 2020-05-11 | 2022-12-09 | 神州细胞工程有限公司 | 通过与改变的Fc片段形成融合蛋白增强蛋白/肽抗原免疫原性的方法 |
JP7048665B2 (ja) * | 2020-05-22 | 2022-04-05 | ゲンマブ ビー.ブイ. | ヒトIgG1 Fc領域変異体およびその使用 |
WO2022000136A1 (en) * | 2020-06-28 | 2022-01-06 | Dingfu Biotarget Co., Ltd. | Methods and compositions for cancer treatment |
US20230293680A1 (en) | 2020-07-23 | 2023-09-21 | Genmab B.V. | A composition of anti-dr5 antibodies and an immunomodulatory imide drug for use in treating multiple myeloma |
GB2616128A (en) | 2020-08-26 | 2023-08-30 | Marengo Therapeutics Inc | Antibody molecules that bind to NKp30 and uses thereof |
JP2023542080A (ja) | 2020-08-26 | 2023-10-05 | マレンゴ・セラピューティクス,インコーポレーテッド | カルレティキュリンに結合する多機能性分子およびその使用 |
CN116761818A (zh) | 2020-08-26 | 2023-09-15 | 马伦戈治疗公司 | 检测trbc1或trbc2的方法 |
EP4221742A1 (en) | 2020-10-02 | 2023-08-09 | Genmab A/S | Antibodies capable of binding to ror2 and bispecific antibodies binding to ror2 and cd3 |
US20220275090A1 (en) | 2021-02-22 | 2022-09-01 | Janssen Biotech, Inc. | Combination Therapies with Anti-CD38 Antibodies and PARP or Adenosine Receptor Inhibitors |
EP4320147A2 (en) | 2021-04-08 | 2024-02-14 | Marengo Therapeutics, Inc. | Multifunctional molecules binding to tcr and uses thereof |
CA3225254A1 (en) | 2021-07-13 | 2023-01-19 | BioNTech SE | Multispecific binding agents against cd40 and cd137 in combination therapy for cancer |
KR20240051280A (ko) | 2021-09-06 | 2024-04-19 | 젠맵 에이/에스 | Cd27과 결합할 수 있는 항체, 그의 변이체 및 그의 용도 |
WO2023057534A1 (en) | 2021-10-06 | 2023-04-13 | Genmab A/S | Multispecific binding agents against pd-l1 and cd137 in combination |
US20230136301A1 (en) | 2021-11-03 | 2023-05-04 | Janssen Biotech, Inc. | Corticosteriod Reduction in Treatment with Anti-CD38 Antibody |
WO2023218051A1 (en) | 2022-05-12 | 2023-11-16 | Genmab A/S | Binding agents capable of binding to cd27 in combination therapy |
WO2023218046A1 (en) | 2022-05-12 | 2023-11-16 | Genmab A/S | Binding agents capable of binding to cd27 in combination therapy |
WO2023217987A1 (en) | 2022-05-12 | 2023-11-16 | BioNTech SE | Monoclonal antibodies directed against programmed death-1 protein and their use in medicine |
WO2023232631A1 (en) * | 2022-06-01 | 2023-12-07 | Julius-Maximilians-Universität Würzburg | Antibody-based soluble and membrane-bound tweak mimicking agonists with fcyr-independent activity |
CN117430710A (zh) * | 2022-07-21 | 2024-01-23 | 中国医学科学院医药生物技术研究所 | 一种针对Trop2的单克隆抗体及其应用 |
WO2024094660A1 (en) | 2022-10-31 | 2024-05-10 | Genmab A/S | Cd38 antibodies and uses thereof |
Family Cites Families (115)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4179337A (en) | 1973-07-20 | 1979-12-18 | Davis Frank F | Non-immunogenic polypeptides |
JPS5896026A (ja) | 1981-10-30 | 1983-06-07 | Nippon Chemiphar Co Ltd | 新規ウロキナ−ゼ誘導体およびその製造法ならびにそれを含有する血栓溶解剤 |
US4609546A (en) | 1982-06-24 | 1986-09-02 | Japan Chemical Research Co., Ltd. | Long-acting composition |
US4681581A (en) | 1983-12-05 | 1987-07-21 | Coates Fredrica V | Adjustable size diaper and folding method therefor |
US4766106A (en) | 1985-06-26 | 1988-08-23 | Cetus Corporation | Solubilization of proteins for pharmaceutical compositions using polymer conjugation |
US5776093A (en) | 1985-07-05 | 1998-07-07 | Immunomedics, Inc. | Method for imaging and treating organs and tissues |
US4735210A (en) | 1985-07-05 | 1988-04-05 | Immunomedics, Inc. | Lymphographic and organ imaging method and kit |
US5101827A (en) | 1985-07-05 | 1992-04-07 | Immunomedics, Inc. | Lymphographic and organ imaging method and kit |
US5648471A (en) | 1987-12-03 | 1997-07-15 | Centocor, Inc. | One vial method for labeling antibodies with Technetium-99m |
US5843708A (en) * | 1988-01-05 | 1998-12-01 | Ciba-Geigy Corporation | Chimeric antibodies |
GB8823869D0 (en) | 1988-10-12 | 1988-11-16 | Medical Res Council | Production of antibodies |
JP3070763B2 (ja) | 1989-08-09 | 2000-07-31 | ロメッド インコーポレイティド | テクネチウムまたはレニウムでの抗体または他のタンパク質の直接放射能標識 |
US6300129B1 (en) | 1990-08-29 | 2001-10-09 | Genpharm International | Transgenic non-human animals for producing heterologous antibodies |
US5789650A (en) | 1990-08-29 | 1998-08-04 | Genpharm International, Inc. | Transgenic non-human animals for producing heterologous antibodies |
US5770429A (en) | 1990-08-29 | 1998-06-23 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
US5874299A (en) | 1990-08-29 | 1999-02-23 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
US5877397A (en) | 1990-08-29 | 1999-03-02 | Genpharm International Inc. | Transgenic non-human animals capable of producing heterologous antibodies of various isotypes |
US5814318A (en) | 1990-08-29 | 1998-09-29 | Genpharm International Inc. | Transgenic non-human animals for producing heterologous antibodies |
US5633425A (en) | 1990-08-29 | 1997-05-27 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
US5625126A (en) | 1990-08-29 | 1997-04-29 | Genpharm International, Inc. | Transgenic non-human animals for producing heterologous antibodies |
US5661016A (en) | 1990-08-29 | 1997-08-26 | Genpharm International Inc. | Transgenic non-human animals capable of producing heterologous antibodies of various isotypes |
EP0546073B1 (en) | 1990-08-29 | 1997-09-10 | GenPharm International, Inc. | production and use of transgenic non-human animals capable of producing heterologous antibodies |
US5545806A (en) | 1990-08-29 | 1996-08-13 | Genpharm International, Inc. | Ransgenic non-human animals for producing heterologous antibodies |
WO1992022645A1 (en) | 1991-06-14 | 1992-12-23 | Genpharm International, Inc. | Transgenic immunodeficient non-human animals |
CA2113113A1 (en) | 1991-07-08 | 1993-01-21 | Simon W. Kantor | Thermotropic liquid crystal segmented block copolymer |
US5733743A (en) | 1992-03-24 | 1998-03-31 | Cambridge Antibody Technology Limited | Methods for producing members of specific binding pairs |
US5635483A (en) | 1992-12-03 | 1997-06-03 | Arizona Board Of Regents Acting On Behalf Of Arizona State University | Tumor inhibiting tetrapeptide bearing modified phenethyl amides |
US5780588A (en) | 1993-01-26 | 1998-07-14 | Arizona Board Of Regents | Elucidation and synthesis of selected pentapeptides |
JPH08509612A (ja) | 1993-04-26 | 1996-10-15 | ジェンファーム インターナショナル インコーポレイテッド | 異種抗体を産生することができるトランスジェニック非ヒト動物 |
US6214345B1 (en) | 1993-05-14 | 2001-04-10 | Bristol-Myers Squibb Co. | Lysosomal enzyme-cleavable antitumor drug conjugates |
US5663149A (en) | 1994-12-13 | 1997-09-02 | Arizona Board Of Regents Acting On Behalf Of Arizona State University | Human cancer inhibitory pentapeptide heterocyclic and halophenyl amides |
IL132560A0 (en) | 1997-05-02 | 2001-03-19 | Genentech Inc | A method for making multispecific antibodies having heteromultimeric and common components |
ES2532910T3 (es) | 1998-04-02 | 2015-04-01 | Genentech, Inc. | Variantes de anticuerpos y fragmentos de los mismos |
WO1999054342A1 (en) | 1998-04-20 | 1999-10-28 | Pablo Umana | Glycosylation engineering of antibodies for improving antibody-dependent cellular cytotoxicity |
US6737056B1 (en) * | 1999-01-15 | 2004-05-18 | Genentech, Inc. | Polypeptide variants with altered effector function |
ES2694002T3 (es) * | 1999-01-15 | 2018-12-17 | Genentech, Inc. | Polipéptido que comprende una región Fc de IgG1 humana variante |
ES2568899T3 (es) | 1999-04-09 | 2016-05-05 | Kyowa Hakko Kirin Co., Ltd. | Procedimiento para controlar la actividad de una molécula inmunofuncional |
CA2380813A1 (en) | 1999-07-29 | 2001-02-08 | Medarex, Inc. | Human monoclonal antibodies to her2/neu |
ES2282133T3 (es) | 1999-08-24 | 2007-10-16 | Medarex, Inc. | Anticuerpos frente a la ctla-4 humano y sus usos. |
JP4668498B2 (ja) | 1999-10-19 | 2011-04-13 | 協和発酵キリン株式会社 | ポリペプチドの製造方法 |
ES2651952T3 (es) | 2000-10-06 | 2018-01-30 | Kyowa Hakko Kirin Co., Ltd. | Células que producen unas composiciones de anticuerpo |
US6946292B2 (en) | 2000-10-06 | 2005-09-20 | Kyowa Hakko Kogyo Co., Ltd. | Cells producing antibody compositions with increased antibody dependent cytotoxic activity |
CA2424977C (en) | 2000-10-06 | 2008-03-18 | Kyowa Hakko Kogyo Co., Ltd. | Process for purifying antibody |
CA2430013C (en) | 2000-11-30 | 2011-11-22 | Medarex, Inc. | Transgenic transchromosomal rodents for making human antibodies |
PT1355919E (pt) | 2000-12-12 | 2011-03-02 | Medimmune Llc | Moléculas com semivida longa, composições que as contêm e suas utilizações |
EP1243276A1 (en) | 2001-03-23 | 2002-09-25 | Franciscus Marinus Hendrikus De Groot | Elongated and multiple spacers containing activatible prodrugs |
CN101671335A (zh) | 2001-05-31 | 2010-03-17 | 梅达莱克斯公司 | 细胞毒素、其有用的前体药物、连接基团和稳定剂 |
KR20090125840A (ko) | 2001-06-13 | 2009-12-07 | 젠맵 에이/에스 | 표피 성장 인자 수용체 (egfr)에 대한 인간 모노클로날 항체 |
US7595378B2 (en) | 2001-06-13 | 2009-09-29 | Genmab A/S | Human monoclonal antibodies to epidermal growth factor receptor (EGFR) |
CN100423777C (zh) | 2001-10-25 | 2008-10-08 | 杰南技术公司 | 糖蛋白组合物 |
AU2003217912A1 (en) * | 2002-03-01 | 2003-09-16 | Xencor | Antibody optimization |
US20040132101A1 (en) * | 2002-09-27 | 2004-07-08 | Xencor | Optimized Fc variants and methods for their generation |
JP4836451B2 (ja) | 2002-07-18 | 2011-12-14 | メルス ベー ヴェー | 抗体混合物の組換え生産 |
PT1545613E (pt) | 2002-07-31 | 2011-09-27 | Seattle Genetics Inc | Conjugados de auristatina e sua utilização para tratamento do cancro, de uma doença autoimune ou de uma doença infecciosa |
CA2502552C (en) | 2002-10-17 | 2019-02-12 | Genmab A/S | Human monoclonal antibodies against cd20 |
CA2506080A1 (en) | 2002-11-14 | 2004-05-27 | Syntarga B.V. | Prodrugs built as multiple self-elimination-release spacers |
ES2401136T3 (es) | 2002-11-15 | 2013-04-17 | Genmab A/S | Anticuerpos monoclonales humanos contra CD25 |
ES2373947T3 (es) | 2002-12-16 | 2012-02-10 | Genmab A/S | Anticuerpos monoclonales humanos contra interleucina 8 (il-8). |
SG10201701737XA (en) | 2003-11-06 | 2017-04-27 | Seattle Genetics Inc | Monomethylvaline compounds capable of conjugation to ligands |
EP2385069A3 (en) * | 2003-11-12 | 2012-05-30 | Biogen Idec MA Inc. | Neonatal Fc rReceptor (FcRn)- binding polypeptide variants, dimeric Fc binding proteins and methods related thereto |
CN101124245A (zh) * | 2003-11-12 | 2008-02-13 | 比奥根艾迪克Ma公司 | 新生儿Fc受体(FcRn)-结合多肽变体、二聚体Fc结合蛋白及其相关方法 |
SI1706424T1 (sl) | 2004-01-12 | 2010-01-29 | Applied Molecular Evolution | Variante fc regij |
EP1740946B1 (en) | 2004-04-20 | 2013-11-06 | Genmab A/S | Human monoclonal antibodies against cd20 |
WO2006020114A2 (en) | 2004-08-04 | 2006-02-23 | Applied Molecular Evolution, Inc. | Variant fc regions |
EP2332985A3 (en) | 2004-11-12 | 2012-01-25 | Xencor, Inc. | Fc variants with altered binding to FcRn |
US7741568B2 (en) | 2005-01-13 | 2010-06-22 | The Wiremold Company | Downward facing receptacle assembly for cable raceway |
SI2567976T1 (sl) | 2005-03-23 | 2017-11-30 | Genmab A/S | Protitelesa usmerjena proti cd38 za zdravljenje multiplega mieloma |
US20110123440A1 (en) | 2005-03-29 | 2011-05-26 | Genevieve Hansen | Altered Antibody FC Regions and Uses Thereof |
AU2006232287B2 (en) | 2005-03-31 | 2011-10-06 | Chugai Seiyaku Kabushiki Kaisha | Methods for producing polypeptides by regulating polypeptide association |
EP1888649A2 (en) | 2005-05-09 | 2008-02-20 | GlycArt Biotechnology AG | Antigen binding molecules having modified fc regions and altered binding to fc receptors |
EP1899477A4 (en) | 2005-07-01 | 2010-01-20 | Medimmune Inc | INTEGRATED APPROACH FOR GENERATING MULTIDOMAIN PROTEIN THERAPEUTIC APPLICATIONS |
WO2007018431A2 (en) | 2005-08-05 | 2007-02-15 | Syntarga B.V. | Triazole-containing releasable linkers and conjugates comprising the same |
US7612181B2 (en) | 2005-08-19 | 2009-11-03 | Abbott Laboratories | Dual variable domain immunoglobulin and uses thereof |
EP1973576B1 (en) | 2005-11-28 | 2019-05-15 | Genmab A/S | Recombinant monovalent antibodies and methods for production thereof |
MX2008009956A (es) | 2006-02-02 | 2008-12-12 | Syntarga Bv | Analogos de cc-1065 solubles en agua y sus conjugados. |
JP5374359B2 (ja) | 2006-03-17 | 2013-12-25 | バイオジェン・アイデック・エムエイ・インコーポレイテッド | 安定化されたポリペプチド化合物 |
PL1999154T3 (pl) | 2006-03-24 | 2013-03-29 | Merck Patent Gmbh | Skonstruowane metodami inżynierii heterodimeryczne domeny białkowe |
AT503902B1 (de) | 2006-07-05 | 2008-06-15 | F Star Biotech Forsch & Entw | Verfahren zur manipulation von immunglobulinen |
WO2008090958A1 (ja) | 2007-01-24 | 2008-07-31 | Kyowa Hakko Kirin Co., Ltd. | ドメイン交換された遺伝子組換え抗体組成物 |
EP2087111A2 (en) * | 2007-03-19 | 2009-08-12 | Medimmune Limited | Polypeptide variants |
NZ614857A (en) | 2007-03-29 | 2015-04-24 | Genmab As | Bispecific antibodies and methods for production thereof |
JP5718637B2 (ja) | 2007-06-21 | 2015-05-13 | マクロジェニクス,インコーポレーテッド | 共有結合型ダイアボディおよびその使用 |
WO2009006520A1 (en) | 2007-07-03 | 2009-01-08 | Medimmune, Llc | Hinge domain engineering |
US8680293B2 (en) | 2007-08-01 | 2014-03-25 | Syntarga B.V. | Substituted CC-1065 analogs and their conjugates |
JP5588866B2 (ja) | 2007-08-10 | 2014-09-10 | メダレックス エル.エル.シー. | Hco32およびhco27、ならびに関連実施例 |
PL2235064T3 (pl) * | 2008-01-07 | 2016-06-30 | Amgen Inc | Sposób otrzymywania cząsteczek przeciwciał z heterodimerycznymi fc z zastosowaniem kierujących efektów elektrostatycznych |
DE102008039957A1 (de) | 2008-08-27 | 2010-03-04 | Continental Automotive Gmbh | Verfahren zur Ermittlung eines Unfallschwerekriteriums mittels eines Beschleunigungssignals und eines Körperschallsignals |
JP5397668B2 (ja) | 2008-09-02 | 2014-01-22 | ソニー株式会社 | 記憶素子および記憶装置 |
AU2009303526B2 (en) * | 2008-10-14 | 2015-01-15 | Genentech, Inc. | Immunoglobulin variants and uses thereof |
PL2344478T3 (pl) | 2008-11-03 | 2018-02-28 | Syntarga B.V. | Analogi CC-1065 oraz ich koniugaty |
UA109633C2 (uk) | 2008-12-09 | 2015-09-25 | Антитіло людини проти тканинного фактора | |
RU2593720C2 (ru) | 2008-12-19 | 2016-08-10 | Макродженикс, Инк. | Ковалентные диантитела и их применение |
EP2233500A1 (en) * | 2009-03-20 | 2010-09-29 | LFB Biotechnologies | Optimized Fc variants |
EP2424567B1 (en) | 2009-04-27 | 2018-11-21 | OncoMed Pharmaceuticals, Inc. | Method for making heteromultimeric molecules |
MX2011014008A (es) | 2009-06-26 | 2012-06-01 | Regeneron Pharma | Anticuerpos biespecificos facilmente aislados con formato de inmunoglobulina original. |
WO2011028952A1 (en) | 2009-09-02 | 2011-03-10 | Xencor, Inc. | Compositions and methods for simultaneous bivalent and monovalent co-engagement of antigens |
KR20120123299A (ko) | 2009-12-04 | 2012-11-08 | 제넨테크, 인크. | 다중특이적 항체, 항체 유사체, 조성물 및 방법 |
US8362210B2 (en) | 2010-01-19 | 2013-01-29 | Xencor, Inc. | Antibody variants with enhanced complement activity |
EP3511342B1 (en) | 2010-03-10 | 2024-01-17 | Genmab A/S | Monoclonal antibodies against c-met |
AR080794A1 (es) | 2010-03-26 | 2012-05-09 | Hoffmann La Roche | Anticuerpos bivalentes biespecificos anti- vegf/ anti-ang-2 |
BR112012026766B1 (pt) | 2010-04-20 | 2021-11-03 | Genmab A/S | Métodos in vitro para gerar um anticorpo igg heterodimérico, para a seleção de um anticorpo biespecífico, vetor de expressão, anticorpo igg heterodimérico, composição farmacêutica, e, uso de um anticorpo igg heterodimérico |
CA2797981C (en) | 2010-05-14 | 2019-04-23 | Rinat Neuroscience Corporation | Heterodimeric proteins and methods for producing and purifying them |
JP6082344B2 (ja) | 2010-05-27 | 2017-02-15 | ゲンマブ エー/エス | Her2エピトープに対するモノクローナル抗体 |
CN107253992B (zh) | 2010-05-27 | 2022-03-11 | 根马布股份公司 | 针对her2的单克隆抗体 |
CA2802782C (en) | 2010-06-15 | 2018-03-13 | Genmab A/S | Human antibody drug conjugates against tissue factor |
MX340558B (es) | 2010-08-24 | 2016-07-14 | F Hoffmann-La Roche Ag * | Anticuerpos biespecificos que comprenden fragmento fv estabilizado con disulfuro. |
WO2012025525A1 (en) | 2010-08-24 | 2012-03-01 | Roche Glycart Ag | Activatable bispecific antibodies |
CN103429620B (zh) * | 2010-11-05 | 2018-03-06 | 酵活有限公司 | 在Fc结构域中具有突变的稳定异源二聚的抗体设计 |
CA2830254C (en) * | 2011-03-16 | 2019-09-10 | Amgen Inc. | Fc variants |
CN102250246A (zh) | 2011-06-10 | 2011-11-23 | 常州亚当生物技术有限公司 | 抗VEGF/PDGFRβ双特异性抗体及其应用 |
UA117901C2 (uk) | 2011-07-06 | 2018-10-25 | Ґенмаб Б.В. | Спосіб посилення ефекторної функції вихідного поліпептиду, його варіанти та їх застосування |
EP2869845B1 (en) | 2012-07-06 | 2019-08-28 | Genmab B.V. | Dimeric protein with triple mutations |
AU2013372331A1 (en) | 2013-01-10 | 2015-07-23 | Genmab B.V. | Human IgG1 Fc region variants and uses thereof |
CA3007033A1 (en) * | 2015-12-01 | 2017-06-08 | Genmab B.V. | Anti-dr5 antibodies and methods of use thereof |
BR112019020219A2 (pt) * | 2017-03-31 | 2020-11-24 | Genmab Holding B.V. | anticorpo biespecífico, anticorpo anti-cd37, composição farmacêutica, uso do anticorpo biespecífico, do anticorpo anti-cd37 ou da composição farmacêutica, método para induzir a morte celular, ou inibir o crescimento e/ou a proliferação de uma célula tumoral que expressa cd37, método de tratamento, construto de ácido nucleico, vetor de expressão, célula hospedeira, anticorpo anti-idiotípico, e, método in vitro para detectar a presença de um antígeno cd37 humano ou uma célula que expressa cd37 humano. |
-
2012
- 2012-06-07 UA UAA201401075A patent/UA117901C2/uk unknown
- 2012-07-06 WO PCT/EP2012/063339 patent/WO2013004842A2/en active Application Filing
- 2012-07-06 CA CA2840147A patent/CA2840147A1/en active Pending
- 2012-07-06 MX MX2013014961A patent/MX357944B/es active IP Right Grant
- 2012-07-06 CN CN202010835726.2A patent/CN112239496A/zh active Pending
- 2012-07-06 SG SG10201605572TA patent/SG10201605572TA/en unknown
- 2012-07-06 JP JP2014517839A patent/JP6243330B2/ja active Active
- 2012-07-06 KR KR1020147002803A patent/KR102163669B1/ko active IP Right Grant
- 2012-07-06 AU AU2012280222A patent/AU2012280222B8/en active Active
- 2012-07-06 EP EP21168872.6A patent/EP3970746A3/en active Pending
- 2012-07-06 BR BR112014000264A patent/BR112014000264A2/pt not_active Application Discontinuation
- 2012-07-06 PT PT127400927T patent/PT2729170T/pt unknown
- 2012-07-06 DK DK12740092.7T patent/DK2729170T3/da active
- 2012-07-06 CN CN201610439143.1A patent/CN106084039B/zh active Active
- 2012-07-06 IN IN807CHN2014 patent/IN2014CN00807A/en unknown
- 2012-07-06 RS RS20220267A patent/RS63044B1/sr unknown
- 2012-07-06 ES ES12740092T patent/ES2908876T3/es active Active
- 2012-07-06 CN CN201280043485.1A patent/CN104220093B/zh active Active
- 2012-07-06 EA EA201400108A patent/EA201400108A1/ru unknown
- 2012-07-06 SI SI201231988T patent/SI2729170T1/sl unknown
- 2012-07-06 US US14/130,543 patent/US10759867B2/en active Active
- 2012-07-06 KR KR1020227039815A patent/KR20220158849A/ko not_active Application Discontinuation
- 2012-07-06 PL PL12740092T patent/PL2729170T3/pl unknown
- 2012-07-06 EP EP12740092.7A patent/EP2729170B1/en active Active
-
2013
- 2013-12-17 ZA ZA2013/09499A patent/ZA201309499B/en unknown
-
2017
- 2017-08-04 JP JP2017151418A patent/JP6586442B2/ja active Active
- 2017-12-04 AU AU2017272140A patent/AU2017272140B2/en active Active
-
2019
- 2019-12-17 AU AU2019283809A patent/AU2019283809A1/en not_active Abandoned
-
2020
- 2020-07-06 US US16/921,154 patent/US20210163619A1/en active Pending
-
2022
- 2022-02-10 AU AU2022200869A patent/AU2022200869A1/en active Pending
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HUS2100034I1 (hu) | ANGPTL3-ellenes antitestek és alkalmazásaik | |
IL288203A (en) | Meditops and Meditop binding antibodies and their use | |
IL281250A (en) | Anti-PHF-tau antibodies and uses thereof | |
DK2729170T3 (en) | Antibody variants and uses thereof | |
IL232399A0 (en) | Anti-2fgfr antibodies and their use | |
EP2756094A4 (en) | ANTI-B7-H4 ANTIBODIES AND USES THEREOF | |
IL231777B (en) | Antibodies against a1tl and their uses | |
IL229844B (en) | Anti-psgl-1 antibodies and their use | |
HK1199842A1 (en) | Anti-siglec-15 antibodies and uses thereof -15 | |
EP2693879A4 (en) | MIGRASTATINES AND THEIR USES |